首页> 外文期刊>Thrombosis >Anticoagulation for Prosthetic Valves
【24h】

Anticoagulation for Prosthetic Valves

机译:人工瓣膜抗凝

获取原文
       

摘要

Implantation of prosthetic valve requires consideration for anticoagulation. The current guideline recommends warfarin on all mechanical valves. Dabigatran is the new generation anticoagulation medication which is taken orally and does not require frequent monitoring. This drug is approved for treatment for atrial fibrillation and venous thromboembolism, but the latest large trial showed that this drug increases adverse events when used for mechanical valve anticoagulation. On-X valve is the new generation mechanical valve which is considered to require less anticoagulation due to its flow dynamics. The latest study showed that lower anticoagulation level lowers the incidence of bleeding, while the risk of thromboembolism and thrombosis remained the same. Anticoagulation poses dilemma in cases such as pregnancy and major bleeding event. During pregnancy, warfarin can be continued throughout pregnancy and switched to heparin derivative during 6–12 weeks and >36 weeks of gestation. Warfarin can be safely started after 1-2 weeks of discontinuation following major bleeding episode.
机译:人工瓣膜的植入需要考虑抗凝作用。当前指南建议在所有机械阀上使用华法林。达比加群是新一代口服抗凝药物,不需要经常监测。该药物被批准用于房颤和静脉血栓栓塞的治疗,但最新的大型试验表明,该药物用于机械瓣膜抗凝治疗时会增加不良反应。 On-X阀是新一代机械阀,由于其流动动力学而被认为需要较少的抗凝作用。最新研究表明,较低的抗凝水平可降低出血的发生率,而血栓栓塞和血栓形成的风险保持不变。在怀孕和重大出血事件等情况下,抗凝药会带来两难境地。在妊娠期间,华法林可在整个妊娠期间继续使用,并在妊娠6-12周和> 36周时改用肝素衍生物。大出血发作后停药1-2周后,可以安全地开始使用华法林。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号